https://www.finanzen.net/news/acelyrin-news
ACELYRIN AKTIE News | aktuelle Nachrichten | Ticker | A3EDH4
aktuelle nachrichtenacelyrinaktienewsticker
https://stockanalysis.com/stocks/slrn/
Acelyrin (SLRN) Stock Price & Overview
Get the latest Solar 18 Corporation (SLRN) stock price with news, financials and other important investing information.
stock priceacelyrinslrnoverview
https://www.fiercebiotech.com/biotech/acelyrin-drops-two-izokibep-indications-and-slashes-staff-focus-looming-fight-amgen
Acelyrin drops izokibep, lays off 3rd of staff
Aug 13, 2024 - Despite promising phase 3 data, the California biotech is ending pursuit of two izokibep indications and laying off staff in favor of lonigutamab.
acelyrindropsizokibeplays3rd
https://www.biospace.com/business/nasdaq-neophytes-acelyrin-alumis-merge-to-tackle-immune-mediated-diseases
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases - BioSpace
Feb 7, 2025 - Alumis held its initial public offering in June last year, while Acelyrin debuted on the Nasdaq in mid-2023.
immune mediatednasdaqneophytesacelyrinmerge
https://www.biospace.com/acelyrin-inc-announces-long-term-32-week-data-from-the-phase-2b-trial-of-izokibep-in-hidradenitis-suppurativa-demonstrating-sustained-responses-and-deepening-clinical-benefit-improving-quality-of-life-for-patients
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis...
Mar 11, 2024 - ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...
https://www.biospace.com/acelyrin-inc-to-report-first-quarter-2024-financial-results-and-corporate-update-on-may-13-2024
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024...
Apr 29, 2024 - LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development...